Immunotherapy in Treating Patients With Resected Liver Metastases From Colon Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed adenocarcinoma of the colon metastatic to the liver that expresses carcinoembryonic antigen (CEA) after resection with curative intent
• * At least 50% of the tumor cells must stain positive for CEA with at least moderate intensity
• No gross residual disease after surgery
• PATIENT CHARACTERISTICS:
• Age:
• 18 and over
• Performance status:
• Karnofsky 70-100%
• Life expectancy:
• Greater than 6 months
• Hematopoietic:
• Absolute neutrophil count at least 1000/mm 3
• Hemoglobin at least 9 g/dL
• Platelet count at least 100,000/mm\^3
• Hepatic:
• Bilirubin less than 2.0 mg/dL
• No chronic or acute hepatic disease
• Renal:
• Creatinine less than 2.5 mg/dL
• Cardiovascular:
• No chronic or acute cardiac disease (New York Heart Association class III or IV)
• Pulmonary:
• No chronic or acute pulmonary illness such as asthma or chronic obstructive pulmonary disease
• Other:
• Not pregnant or nursing
• No other prior or concurrent malignancy except nonmelanoma skin cancer or controlled superficial bladder cancer within the past 5 years
• No history of autoimmune disease such as inflammatory bowel disease, systemic lupus erythematosus, ankylosing spondylitis, scleroderma, and multiple sclerosis
• No active acute or chronic infection such as urinary tract infection, HIV, or viral hepatitis
• No active infectious enteritis or eosinophilic enteritis
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• No other concurrent immunotherapy
• Chemotherapy:
• No concurrent chemotherapy
• At least 6 weeks since prior chemotherapy
• Endocrine therapy:
• No concurrent steroid therapy (or any other immunosuppressives)
• At least 6 weeks since prior steroid therapy
• Radiotherapy:
• No concurrent radiotherapy
• At least 6 weeks since prior radiotherapy
• Surgery:
• Recovered from prior surgery